Grover S, Rimoldi J M, Molinero A A, Chaudhary A G, Kingston D G, Hamel E
Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Biochemistry. 1995 Mar 28;34(12):3927-34. doi: 10.1021/bi00012a009.
Our finding that an analog of paclitaxel (Taxol) modified at position C-2 (2-debenzoyl-2-(m-azidobenzoyl)paclitaxel) was substantially more active than paclitaxel in promoting tubulin assembly [Chaudhary et al. (1994) J. Am. Chem. Soc. 116, 4097-4098] led us to perform an analysis of the modulating effects of microtubule-associated proteins, GTP, and temperature on assembly and polymer stability. The analog always showed superior activity to paclitaxel in inducing polymerization where it fails to occur without drug, probably indicating a greater ability than paclitaxel to "hypernucleate" assembly. In contrast, much smaller differences in effects on polymer stability were observed. The analysis was extended to a large series of derivatives modified at positions C-2, C-7, C-10, and C-3', including docetaxel, a clinically important analog of paclitaxel. While analog stabilization of polymer was frequently observed, neither qualitative nor quantitative analysis of this property reliable predicted whether a compound would have enhanced hypernucleation activity relative to that of paclitaxel. Stabilization was often observed at substoichiometric analog concentrations, while even superstoichiometric concentrations of most compounds failed to induce extensive tubulin polymerization at low temperatures or in the absence of microtubule-associated proteins or GTP. Docetaxel was intermediate in activity between paclitaxel and 2-debenzoyl-2-(m-azidobenzoyl)paclitaxel in promoting assembly reactions. We conclude that the hypernucleation of tubulin assembly and polymer stabilization observed with paclitaxel represent two distinct properties of the drug. Our findings suggest that paclitaxel, docetaxel, and 2-debenzoyl-2-(m-azidobenzoyl)paclitaxel are able to interact with progressively smaller assemblages of tubulin at low temperatures or in the absence of microtubule-associated proteins or GTP.
我们发现,在C-2位修饰的紫杉醇类似物(2-去苯甲酰基-2-(间叠氮苯甲酰基)紫杉醇)在促进微管蛋白组装方面比紫杉醇活性显著更高[乔杜里等人(1994年)《美国化学会志》116,4097 - 4098],这促使我们分析微管相关蛋白、GTP和温度对组装及聚合物稳定性的调节作用。在诱导聚合反应方面,该类似物始终表现出比紫杉醇更优越的活性,在无药物时聚合反应无法发生的情况下,它却能诱导聚合,这可能表明它比紫杉醇有更强的“超成核”组装能力。相比之下,在对聚合物稳定性的影响上观察到的差异要小得多。该分析扩展到了一系列在C-2、C-7、C-10和C-3'位修饰的衍生物,包括多西他赛,它是紫杉醇临床上重要的类似物。虽然经常观察到聚合物的类似物稳定作用,但对该性质的定性或定量分析都无法可靠地预测一种化合物相对于紫杉醇是否会有增强的超成核活性。在亚化学计量的类似物浓度下经常观察到稳定作用,而即使是超化学计量浓度的大多数化合物在低温下或在没有微管相关蛋白或GTP的情况下也无法诱导广泛的微管蛋白聚合。多西他赛在促进组装反应方面的活性介于紫杉醇和2-去苯甲酰基-2-(间叠氮苯甲酰基)紫杉醇之间。我们得出结论,紫杉醇观察到的微管蛋白组装超成核和聚合物稳定作用代表了该药物的两种不同性质。我们的研究结果表明,紫杉醇、多西他赛和2-去苯甲酰基-2-(间叠氮苯甲酰基)紫杉醇在低温下或在没有微管相关蛋白或GTP的情况下能够与越来越小的微管蛋白聚集体相互作用。